LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity

The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for innovative projects focused on adding value to biomedical research. The effort wants to contribute to the discovery of drugs for diseases unmet needs, supporting the best biomedical science. Consequently, the Chemostart initiative (http://www.insudpharma.com/es/chemostart#colaboremos) is meant to promoting the best innovative projects. As a result of an extremely competitive assessment of hundreds of ventures, LeadArtis immune-oncology therapeutic project has nominated between the twelve finalist projects and invited to present at the final pitching day to be held on January 31st, 2019.  
LeadArtis is a preclinical stage health biotechnology company located in Madrid (www.leadartis.com) focused on developing tumor targeted multivalent and multispecific immune stimulating antibodies through its unique Trimerbody® technology. The Trimerbodies exhibit excellent antigen binding capacity, functionality and stability.

Latest News

Clave Capital invests in Leadartis in a funding round of more than €1,600,000

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its...

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis

The entry of funds into leadartis' shareholding is part of a round of financing closed by...

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research